Eli Lilly's dulaglutide, a GLP-1 receptor agonist, is being evaluated for pediatric patients with type 2 diabetes mellitus. The pediatric diabetes market is expanding, driven by rising prevalence rates and increasing awareness of diabetes management in children. If successful, dulaglutide could capture significant market share, competing against other GLP-1 receptor agonists and diabetes therapies. The completion of this trial may enhance Eli Lilly's portfolio and strengthen its position in the diabetes market, particularly in the pediatric segment, which is currently underserved. Diligence should focus on potential regulatory hurdles and the competitive landscape, including emerging therapies targeting similar patient populations.